Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Practice Point
  • Published:

What are the effects of cyclooxygenase-2-specific inhibitors on the small bowel?

Nature Clinical Practice Gastroenterology & Hepatology volume 2, pages 212–213 (2005)Cite this article

boxed-textGoldstein JL et al. (2005) Video capsule endoscopy to prospectively assess small bowel injury with celecoxib, naproxen plus omeprazole, and placebo. Clin Gastroenterol Hepatol 3: 133–141

Coxibs should be considered for use in patients with low cardiac risk and increased gastrointestinal risk

This is a preview of subscription content, access via your institution

Access options

Buy this article

  • Purchase on Springer Link
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

References

  1. Scheiman JM (2003) Gastroduodenal safety of cyclooxygenase-2 specific inhibitors. Curr Pharm Des 9: 2197–2206

    Article  CAS  Google Scholar 

  2. Chan FK et al. (2002) Celecoxib versus diclofenac and omeprazole in reducing the risk of recurrent ulcer bleeding in patients with arthritis. N Engl J Med 347: 2104–2110

    Article  CAS  Google Scholar 

  3. Lanas A (2003) Celecoxib versus diclofenac and omeprazole to prevent recurrent ulcer bleeding. N Engl J Med 348: 2464–2466

    Article  Google Scholar 

  4. Laine L et al. (2003) Serious lower gastrointestinal clinical events with nonselective NSAID or coxib use. Gastroenterology 124: 288–292

    Article  CAS  Google Scholar 

  5. Fendrick AM (2004) COX-2 inhibitor use after Vioxx: Careful balance or end of the rope? Am J Manag Care 11(Pt 1): 740–741

    Google Scholar 

Download references

Acknowledgements

The synopsis was written by Rachel Jones, Associate Editor, Nature Clinical Practice.

Author information

Authors and Affiliations

  1. Professor of Medicine, Division of Gastroenterology and Director of Endoscopic Research at the University of Michigan, MI, USA

    James M Scheiman

Authors
  1. James M Scheiman
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to James M Scheiman.

Ethics declarations

Competing interests

JM Scheiman is a Consultant for AstraZeneca, Merck, Novartis, TAP Pharmaceutical Products Inc, Pfizer and The GI Company. He has also received grants/research support in the past from AstraZeneca, Pfizer and Merck.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Scheiman, J. What are the effects of cyclooxygenase-2-specific inhibitors on the small bowel?. Nat Rev Gastroenterol Hepatol 2, 212–213 (2005). https://doi.org/10.1038/ncpgasthep0174

Download citation

  • Received:

  • Accepted:

  • Issue Date:

  • DOI: https://doi.org/10.1038/ncpgasthep0174

Search

Advanced search

Quick links

Nature Briefing

Sign up for the Nature Briefing newsletter — what matters in science, free to your inbox daily.

Get the most important science stories of the day, free in your inbox. Sign up for Nature Briefing